Iodipamide

Summary

Iodipamide (CHEMBL1165268) is an approved small-molecule radioopaque medium (ATC V08AC04).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AC04
• Chemistry: 1139.8 Da · C20H14I6N2O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1165268
Name	Iodipamide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3739
ChEBI	CHEBI:31176
ATC	V08AC04
Molecular formula	C20H14I6N2O6
Molecular weight	1139.8
InChIKey	FFINMCNLQNTKLU-UHFFFAOYSA-N

SMILES: C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I

IUPAC name: 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid

ChEBI definition: An organoiodine compound that is 3-amino-2,4,6-triiodobenzoic acid in which one of the amino hydrogens is substituted by a 6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl group. It is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.

Pharmacological roles (ChEBI): radioopaque medium.

Also known as: Adipiodona, Adipiodone, Cholografin, Iodipamide, NSC-757423, SID11112428, SID47193872, iodipamide, IODIPAMIDE, SID144207053, SID170464888, ADIPIODONE

Parent form; salt/anhydrous children: CHEMBL1200350, CHEMBL1200504, CHEMBL2104843, CHEMBL3989806

Patent coverage: 607 distinct patent families (2,164 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,145 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Thyrotropin receptor, Mitogen-activated protein kinase 1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPK1	5.9	Potency	1259	nM	CHEMBL_ACT_4522283
TSHR	5.2	Potency	6310	nM	CHEMBL_ACT_3920863

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).